LEADER 04509nam 2200613 450 001 9910465429703321 005 20210428234508.0 010 $a1-4963-2443-9 010 $a1-4698-8349-X 035 $a(CKB)2560000000261828 035 $a(EBL)2035673 035 $a(SSID)ssj0001352529 035 $a(PQKBManifestationID)11751539 035 $a(PQKBTitleCode)TC0001352529 035 $a(PQKBWorkID)11310554 035 $a(PQKB)10775191 035 $a(MiAaPQ)EBC2035673 035 $a(Au-PeEL)EBL2035673 035 $a(CaPaEBR)ebr11292951 035 $a(OCoLC)894231911 035 $a(EXLCZ)992560000000261828 100 $a20140307h20152015 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aNuclear oncology /$f[edited by] Cumali Aktolun, MD, MSc, Visiting Professor, Department of Radiology, Molecular Imaging Program at Stanford, School of Medicine, Standford University, Palo Alto, California, Stanley J. Goldsmith, MD, Professor, Department of Radiology and Medicine, Sanford and Joan Weill College of Medicine at Cornell University, Director-Emeritus, Division of Nuclear Medicine and Molecular Imaging, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York 210 1$aPhiladelphia :$cWolters Kluwer,$d[2015] 210 4$d©2015 215 $a1 online resource (733 p.) 300 $aDescription based upon print version of record. 311 $a1-4511-8685-1 320 $aIncludes bibliographical references and index. 327 $aNUCLEAR ONCOLOGY; Contributors; Foreword; Preface; Acknowledgment; Contents; PART I Organ Malignancies; 1 Brain Tumors; 2 Head and Neck Carcinomas; 3 Thyroid Carcinoma; 4 Parathyroid Tumors; 5Esophageal Carcinoma; 6Gastric Carcinoma-I; 7Gastric Carcinoma-II; 8Pancreatic Carcinoma; 9Colorectal Carcinoma; 10Liver Tumors; 11Breast Carcinoma; 12Pulmonary Carcinoma; 13 Renal Carcinoma; 14Bladder Carcinoma; 15Prostate Carcinoma; 16Uterine and Cervical Carcinoma; 17Ovarian Carcinoma; 18Testicular Germ Cell Tumors; 19Tumors of the Adrenal Glands; PART II Malignancies Involving the Entire Body 327 $a20Neuroendocrine Tumors21Lymphoma and Leukemia; 22Melanoma; 23Neuroblastoma; 24Bone Tumors; PART III Special Topics In Nuclear Oncology; 25Pediatric Tumors; 26Cancer of Unknown Primary; 27Assessment of Lymph Nodes in Oncology; 28Sentinel Lymph Node Detection and Imaging in Oncology; 29PET/CT Hybrid Imaging in Radiothe rapy Planning; 30Bone Mineral Densitometry in Oncology; 31Non-FDG PET/CT Imaging in Onc ology; 32Assessment of Response to Antitumor Tr eatment; 33Radionuclide Imaging for the Assessment of Toxicity Due to Chemotherapy 327 $aPART IV Investigative Methods for Studying Tumor Biology and Microenvironment34Radionuclide Imaging of Multidrug Resistance; 35Radionuclide Imaging of Tumor Hypoxia and Its Clinical Implications; 36Radionuclide Imaging of Tumor Cell Apoptosis; 37Radionuclide Imaging of Tumor Angiogenesis; 38Radionuclide Imaging of Tumor Cell Proliferation; 39Radionuclide Imaging of Human Epidermal Receptors; 40Radionuclide Imaging of Integrins; 41 Radionuclide Imaging of Annexins; PART V Technical Issues; 42 Radiochemistry in Nuclear Oncology 327 $a43 Advances in Nuclear and Optical Imaging of Tumors: Multi-Modality, Small-Animal, and Intraoperative TechnologiesINDEX 330 $aNuclear Oncology a contemporary narrative of the role of nuclear medicine in oncology with an emphasis on SPECT/CT and PET/CT with additional comments when appropriate on the potential application of PET/MR and to a lesser degree, targeted radionuclide therapy. This book focuses on the use of radionuclides in the diagnosis and treatment of malignant diseases. It describes relevant approved and investigational clinical applications, instrumentation & technology, chemistry and practical clinical issues in nuclear oncology. The basic science and current research topics of nuclear oncology are add 606 $aCancer$xRadionuclide imaging 606 $aCancer$xRadiotherapy 608 $aElectronic books. 615 0$aCancer$xRadionuclide imaging. 615 0$aCancer$xRadiotherapy. 676 $a616.99/407575 702 $aAktolun$b C$g(Cumali),$f1961- 702 $aGoldsmith$b Stanley J. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910465429703321 996 $aNuclear Oncology$91737662 997 $aUNINA LEADER 02472 am 2200433 n 450 001 9910296439303321 005 20231019220001.0 010 $a2-35412-263-2 024 7 $a10.4000/books.pupvd.6161 035 $a(CKB)4100000007223745 035 $a(FrMaCLE)OB-pupvd-6161 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/40623 035 $a(PPN)23291902X 035 $a(EXLCZ)994100000007223745 100 $a20181218j|||||||| ||| 0 101 0 $afre 135 $auu||||||m|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAlfredo Gangotena, poète équatorien (1904-1944) $eOu l'écriture partagée /$fAdriana Castillo De Berchenko 210 $aPerpignan $cPresses universitaires de Perpignan$d2018 215 $a1 online resource (293 p.) 311 $a2-908912-02-3 330 $aIssu de la haute bourgeoisie terrienne, Alfredo Gangotena, né à Quito (1904-1944), est un poète équatorien bilingue - français-espagnol - d'une rare qualité. Arrivé en France, encore adolescent, il réside à Paris entre 1920 et 1930 et participe activement aux mouvements esthétiques européens d'avant-garde. Auteur d'une production poétique d'une grande beauté - et qui le situe de plein droit aux côtés de Vicente Huidobro, César Vallejo ou Pablo Neruda - Gangotena, jusqu'à aujourd'hui, n'a toujours pas bénéficié de la place qu'il mérite dans les espaces littéraires européen et latino-américain. Cet ouvrage fait le tableau des milieux que Gangotena a fréquentés en Europe et en Amérique latine et analyse les circonstances particulières - et très personnelles - qui ont déterminé sa démarche créatrice. À la lumière de l'ensemble de son ?uvre, l'auteur étudie l'aventure solitaire d'un artiste qui, par l'expérience atroce de l'oubli, l'absence et le Néant, découvre sa vraie identité. 517 $aAlfredo Gangotena, poète équatorien 517 $aAlfredo Gangotena, poète équatorien 606 $aAuthors, Ecuadorian$y20th century$xBiography 610 $aÉquateur 610 $apoésie 610 $aécriture 610 $aartiste 615 0$aAuthors, Ecuadorian$xBiography 700 $aCastillo De Berchenko$b Adriana$0752917 801 0$bFR-FrMaCLE 906 $aBOOK 912 $a9910296439303321 996 $aAlfredo Gangotena, poète équatorien (1904-1944)$93032977 997 $aUNINA